SSY Group Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jiguang Qu

Algemeen directeur

HK$14.7m

Totale compensatie

Percentage CEO-salaris	45.5%
Dienstverband CEO	16yrs
Eigendom CEO	9.5%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	7.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jiguang Qu's beloning veranderd ten opzichte van SSY Group's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2022	HK$15m	HK$7m	HK$1b
Sep 30 2022	n/a	n/a	HK$1b
Jun 30 2022	n/a	n/a	HK$1b
Mar 31 2022	n/a	n/a	HK$933m
Dec 31 2021	HK$7m	HK$7m	HK$786m
Sep 30 2021	n/a	n/a	HK$713m
Jun 30 2021	n/a	n/a	HK$641m
Mar 31 2021	n/a	n/a	HK$626m
Dec 31 2020	HK$7m	HK$7m	HK$612m
Sep 30 2020	n/a	n/a	HK$723m
Jun 30 2020	n/a	n/a	HK$835m
Mar 31 2020	n/a	n/a	HK$985m
Dec 31 2019	HK$13m	HK$6m	HK$1b
Sep 30 2019	n/a	n/a	HK$1b
Jun 30 2019	n/a	n/a	HK$1b
Mar 31 2019	n/a	n/a	HK$963m
Dec 31 2018	HK$17m	HK$6m	HK$912m
Sep 30 2018	n/a	n/a	HK$867m
Jun 30 2018	n/a	n/a	HK$822m
Mar 31 2018	n/a	n/a	HK$743m
Dec 31 2017	HK$12m	HK$6m	HK$665m
Sep 30 2017	n/a	n/a	HK$616m
Jun 30 2017	n/a	n/a	HK$567m
Mar 31 2017	n/a	n/a	HK$528m
Dec 31 2016	HK$33m	HK$6m	HK$490m

Compensatie versus markt: De totale vergoeding ($USD 1.88M ) Jiguang } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.34M ).

Compensatie versus inkomsten: De vergoeding van Jiguang is het afgelopen jaar met meer dan 20% gestegen.

CEO

Jiguang Qu (68 yo)

16yrs

Tenure

HK$14,690,000

Compensatie

Mr. Jiguang Qu has been the Chairman and General Manager of Shijiazhuang Siyao Pharmaceutical Ltd. from January 2000. Mr. Qu serves as the Chairman and Chief Executive Officer of SSY Group Limited.He is...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jiguang Qu	Chairman & CEO	16yrs	HK$14.69m	9.5% $ 157.0m
Hing Yeung Chow	CFO, Company Secretary & Executive Director	1.9yrs	HK$1.10m	geen gegevens
Xuejun Su	Executive Director	8.6yrs	HK$1.68m	0.82% $ 13.6m
Guo Meng	Deputy GM & Executive Director	1.9yrs	HK$1.17m	geen gegevens
Kwok Wai Chow	Independent Non Executive Director	17.8yrs	HK$228.00k	geen gegevens
Yibing Wang	Independent Non Executive Director	16yrs	HK$228.00k	geen gegevens
Hao Feng	Non-Executive Director	5.7yrs	HK$228.00k	geen gegevens
Guangce Jiang	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens

7.1yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LJUI.F wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.1 jaar).

SSY Group Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

SSY Group Limited, Annual General Meeting, May 17, 2024

SSY Group Limited Appoints Liu Wenjun as Non-Executive Director

SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023

SSY Group Limited Announces the Retirement of Mr. Leung Chong Shun as Independent Non-Executive Director, Chairman of the Remuneration Committee of the Company, A Member F the Audit Committee of the Company and A Member of the Nomination Committee

Recent updates

SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg)

SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China

SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024

SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China

SSY Group Limited Provides Update on Product Development

SSY Group Limited, Annual General Meeting, May 17, 2024

SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China

SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market

SSY Group Limited Receives Approval for Gliclazide Tablet

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Provides Update on Product Development

SSY Group Limited Appoints Liu Wenjun as Non-Executive Director

Ssy Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

National Medical Products Administration of China Accepts Application for Phase I Clinical Trial of the SSY Group Limited 'S SYN-045

SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023

SSY Group Limited Obtains Approvals for Drug Production and Registration for Aminophylline Injection

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Tablets from the National Medical Products Administration of China

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Clinical Trial Approval Issued By the National Medical Products Administration of China for Alprostadil Injection

SSY Group Limited Obtains the Approval for Drug Production and Registration for Linezolid and Sodium Chloride Injection (300ml) from the National Medical Products Administration of China

SSY Group Limited Obtains the Approvals for Drug Production and Registration for Tinidazole Tablets (0.5G) and Ornidazole Tablets (0.5G) from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Provides Update on Product Development

Ssy Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 27 September 2023

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report First Half, 2023 Results on Aug 29, 2023

SSY Group Limited Obtains Approval for Drug Production and Registration for Stiripentol for Suspension (500Mg and 250Mg) from the National Medical Products Administration of China

SSY Group Limited Obtains Approval for Drug Production and Registration for Oseltamivir Phosphate for Suspension

SSY Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Citicoline Sodium Injection from the National Medical Products Administration of China

SSY Group Limited Obtains the Approvals for Drug Production and Registration for Urapidil Hydrochloride Injection

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces the Retirement of Mr. Leung Chong Shun as Independent Non-Executive Director, Chairman of the Remuneration Committee of the Company, A Member F the Audit Committee of the Company and A Member of the Nomination Committee

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces the Group's Tinidazole Obtains the Approval for Registration from the National Medical Products Administration of China

SSY Group Limited Updates on Product Development

SSY Group Limited Obtains the Approval for Registration from the National Medical Products Administration of China to Become A Bulk Drug for the Preparations on the Market

Analyse CEO-vergoeding

CEO

Tenure

Compensatie